9723 JJ, GRONINGEN
+31 (0) 50 589 06 12
+31 (0) 50 589 06 13
Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.
AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications.
The introduction of the AGE Reader marks a technological breakthrough and has profound impact on the discovery and clinical intervention of diabetes and other ageing related chronic disorders. This innovative product not only enables instantaneous diagnosis and risk assessment on diabetes and its complications, but also provides clinicians with needed information to make a correct and personalized treatment plan.
Since the CE certification of the AGE Reader in 2006, Diagnoptics has been selling this device to diverse end users in applicable markets. Diagnoptics currently markets 2 models of the AGE Reader: SU and mu.Medical Devices